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General considerations 
Patients admitted at Intensive Care Units (ICUs) often require central venous 
catheterization for multiple purposes, namely administration of medication (such as 
vasopressors, chemotherapy or total parenteral nutrition), infusion of large amounts of 
fluids or blood products, hemodynamic monitoring, dialysis or transvenous cardiac 
pacing. However, infectious complications may follow, ranging from simple catheter 
colonization (significant growth of a microorganism in a culture of the catheter tip, its 
subcutaneous segment or its hub), to local catheter infection (exit-site, tunnel or pocket 
infection and phlebitis) or to sepsis (generalized bloodstream infection, which is 
considered severe when it is associated with organ dysfunction, hypoperfusion or 
hypotension). Ultimately, mortality may result from septic thrombophlebitis, 
endocarditis, metastatic infection (such as lung or brain abscess) and septic shock with 
multiorgan failure. 
Bloodstream infections may be related to the catheter itself (at least, one positive 
culture result obtained from a peripheral vein, clinical manifestations of systemic 
infection and no other detectable source for the bloodstream infection than the 
intravascular catheter) or to the infusate (whenever there is growth of the same 
microorganism both from the infusate and the percutaneously obtained blood samples). 
Nevertheless, the vast majority of catheter-related bloodstream infections (CRBSIs) are 
associated with central venous catheters (CVCs).
1
 The laboratorial confirmation of the 
diagnosis of CRBSI demands one of the following criteria: (1) a positive result of a 
semiquantitative (≥15 colony forming unit per catheter segment) or quantitative (≥102 
cfu per catheter segment) catheter culture, while the same organism is isolated from a 
peripheral blood sample; (2) simultaneously positive quantitative cultures of blood 
samples with a ratio of ≥5:1 (central vs peripheral venous catheter) or (3) differential 
time to positivity (a positive result from a CVC culture obtained at least 2 hours earlier 
than a positive result from the culture of peripheral blood).
2,3
 
 The socio-economic impact of CRBSIs is considerable. In a recent European 
review, data from France, Germany, Italy and the United Kingdom revealed an 
additional length of stay (LOS) of 1.9 to 14 days and extra costs of €4,200 to €13,030 
per CRBSI episode.
4
 This economic burden is in line with data from the United States: 
additional LOS of 2.41 to 8 days and costs that may reach $11,971 to $56,167 per 
episode.
5-7
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Epidemiology and microbiology 
The risk factors for infectious complications of central venous catheterization are 
related to co-existing diseases (such as malignancy, neutropenia and shock), to the 
procedure (use of an aseptic technique during insertion, site of venous access, type of 
catheter material and number of lumens) and to the infused therapy (composition, 
adequate solution preparation and delivery, catheter care during manipulation and 
indwelling time).
8,9
 
In a recent European review, the incidence rate of CRBSIs was estimated at 1.23 
to 4.2 per 1000 catheter days.
4
 A slightly higher incidence rate of 5.0 CRBSIs per 1000 
catheter days was reported from the US.
10
 No reliable data has been available regarding 
Portugal. 
The microbial agents most frequently isolated from CRBSIs are coagulase-
negative staphylococci, Staphylococcus aureus, gram negative bacilli and Candida 
species.
2
 Among a multitude of coagulase-negative staphylococci, Staphylococcus 
epidermidis inhabits the human skin and mucous membranes and leads not only the 
ranking of etiological agents of CRBSIs, but also of contamination of blood cultures.
3
  
S. epidermidis is able to form biofilm easily and, therefore, it is frequently associated 
with colonization of indwelling foreign medical devices such as intravenous catheters.
11
 
Moreover, healthcare related strains of coagulase-negative staphylococci became 
increasingly resistant to antibiotics; vancomycin resistant strains have already been 
reported.
12
 
S. aureus may be found colonizing the nares and skin of humans. It is usually 
associated with more serious infections, ranging from skin and soft tissue infections to 
pneumonia, meningitis, endocarditis and bloodstream infections.
2,13,14
 Currently, more 
than 50% of isolates obtained from ICUs are methicillin-resistant Staphylococcus 
aureus (MRSA).
10
 Infections caused by MRSA increase the mortality, length of 
hospitalization and costs compared with methicillin-sensitive Staphylococcus aureus 
(MSSA) infections.
15
 Therefore, preventive efforts are adopted in order to decrease the 
incidence of MRSA infections, either by widespread decolonization with nasal 
mupirocin or by contact isolation of patients.
16
 
Gram-negative bacilli have also been widely documented as agents of CRBSIs. 
The most frequent isolates are Escherichia coli, Pseudomonas aeruginosa, Klebsiella 
spp., Enterobacter spp. and Acinetobacter baumannii.
16,17
 Infection by Gram negative 
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bacilli more often afflicts patients with a compromised immune system, receiving 
contaminated infusates or placed with tunnelled indwelling devices, while the 
proportion of antibiotic resistant strains is increasing.
18
 A. baumannii is an emerging 
organism responsible for severe CRBSIs and pneumonia, with high rates of multidrug 
resistance (MDR).
19
 Besides being ubiquitous and a frequent patient colonizer, the 
increase in the number of healthcare related infections (HCRIs) caused by A. baumannii 
may be explained by its ability to persist for months in undisturbed surfaces of 
healthcare equipment. Hence, outbreaks in hospital settings are difficult to contain 
because of the environmental contamination by such an agent.
20-22
 
The incidence of invasive fungal HCRIs has risen markedly over the last 10 
years.
23
 The presence of a central venous catheter, prolonged LOS, broad-spectrum 
antibiotic use, burns, ICU stay, administration of parenteral nutrition and neutropenia 
are risk factors for invasive candidosis.
16,24
 Concerning bloodstream infections, Candida 
species are invariably associated with a high mortality rate (39.3 to 44%). C. albicans is 
the most frequent isolate,
25-27
 standing out as the fourth leading cause of CRBSI.
9
 
Among non-albicans species, C. parapsilosis is the most common isolate in Europe.
25
 It 
is often associated with the presence of intravascular catheters or breaks in infection 
control, since C. parapsilosis is most often an exogenous pathogen. C. glabrata usually 
ranks second and its isolation has been related to azole selection pressure.
25,26
 
 
Pathogenesis of CRBSIs 
Contamination of CVCs may occur from several routes: (1) migration of skin organisms 
from the insertion site along the external surface of the catheter, which is the most 
common infection route for short-term CVCs (duration of placement <1 week);
28,29
 (2) 
intraluminal spread from the manipulation of the catheter hub, which may be the 
dominant route for long-term CVC infection (duration of placement >1 week);
30
 rarely, 
(3) haematogenous seeding of the catheter tip from a distant focus of infection
31
 or (4) 
infusate contamination, which may ultimately lead to CRBSIs.
32
 
Among the most relevant pathogenic determinants of CRBSIs, the intrinsic 
virulence factors of microbial agents, human host factors and the material of the catheter 
by itself must be taken into consideration: 
(1) Microorganisms such as coagulase negative staphylococci,
33
 S. aureus
34
 and 
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Candida spp
35
 produce extracellular polymeric substance (EPS), which is an 
exopolysaccharide that contributes to the formation of a biofilm layer.
36,37
 Metallic 
cations from the blood circulation may add to this biofilm and form a dense matrix in 
which microbial agents may stay embedded.
38
 
(2) Some host adhesion proteins, such as fibrin and fibronectin, form a sheath 
around the catheter that promote adherence of microorganisms. This is the case with S. 
aureus, which expresses the clumping factors ClfA and ClfB that bind to host 
adhesins.
39-41
 
(3) Catheter materials that are more thrombogenic or hydrophobic display higher 
vulnerability to microbial adhesion.
42,43
 Moreover, the extent of colonization appears to 
increase with surface roughness because shear forces are locally diminished and the 
adhesion area is higher.
37
 Polyurethane and polytetrafluoroethylene (Teflon
®
) catheters 
have been associated with less infectious complications than catheters made of 
polyvinyl chloride or polyethylene.
44,45
 At present, polyurethane catheters are the most 
frequently used worldwide in medical care. 
 
The role of microbial biofilms 
Microbial biofilms are sessile communities of organisms that are embedded in a matrix 
of extracellular polymers and exhibit an altered phenotype concerning growth rate and 
gene transcription.
36
 The basic structural unit of the biofilm is the microcolony, which is 
encased in the matrix and separated from other colonies by water channels where 
oxygen and nutrients may diffuse.
37
 
 In general, biofilm organisms are more resistant than their planktonic 
counterparts: (1) penetration of antimicrobial agents through the matrix is delayed 
because it works as a diffusional barrier; (2) growth of biofilm organisms is slower 
since nutrient limitation and accumulation of toxic metabolites within the biofilm may 
delay bacterial growth, hindering the uptake of antimicrobial agents.
36
 Moreover, 
biofilms that develop on indwelling medical devices such as CVCs are correlated with 
CRBSI by the following suggested mechanisms: (1) detachment of microbial cells by 
shear stress or changes in substrate concentration in the matrix; (2) production of 
endotoxin by gram-negative bacteria; (3) resistance to the host immune system response 
12 
 
by inhibition of macrophage phagocytosis or antibody activity and (4) promotion of 
antibiotic resistance by plasmid exchange within the niche of microcolonies.
33,36,37,46,47
 
 Several comprehensive strategies have been proposed to control biofilms in 
CRBSIs, either by (1) preventing medical device contamination during insertion steps; 
(2) inhibiting microbial cell attachment to the surface of devices; (3) destructing the 
formed biofilm by killing the microorganisms embedded in the matrix or by (4) 
removing the infected device.
36
 
 
Current strategies for prevention of CRBSIs 
Essentials of CVC management 
Several strategies are strongly recommended and supported by current literature aiming 
an effective reduction of CRBSIs: 
1. Education of healthcare personnel regarding CVC insertion and maintenance, 
with adherence to a catheter care protocol involving strict aseptic technique. 
Trained staff should be periodically assessed for knowledge and commitment to 
guidelines.
48-50
 
2. Benefits of each placement site must be weighed against the risk of mechanical 
and infectious complications: femoral vein catheters have the higher 
colonization rate and the higher risk for deep venous thrombosis; the use of the 
subclavian site is associated with the lowest risk of infection, although 
mechanical complications (such as pneumothorax, subclavian artery puncture, 
subclavian vein laceration or stenosis) should be considered.
51-59
 
3. The use of polyurethane and polytetrafluoroethylene (Teflon®) CVCs is 
associated with less infectious complications, as is the use of the minimum 
number of ports and lumens.
44,60-62
 
4. Superfluous catheters must be promptly removed; replacement of CVCs within 
48h should occur whenever asepsis cannot be ensured.
63-67
 
5. Cleaning the skin with >0.5% chlorhexidine preparation with alcohol and using 
maximal sterile barrier precautions (cap, mask and sterile gown, gloves and full 
body drape) for the insertion of central catheters, with sterile gauze or 
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transparent dressing to cover the catheter site. Hand hygiene procedures (with 
soap or alcohol-based hand rubs) should be undertaken before and after 
manipulation.
66,68-74
 
6. At present, there are no recommendations to routine use of systemic 
antimicrobial prophylaxis, periodical replacement of CVCs or guidewire 
exchanges in order to prevent CRBSIs.
75,76
 
7. Replacement of administration sets should occur within 96-hour to 7-day 
intervals.
77,78
 For blood products or lipid emulsions, tubing should be replaced 
within a maximum of 24 hours.
79,80
 
Other approaches aiming to reduce CRBSIs are available, but are only supported by 
suggestive clinical or epidemiologic studies or by a theoretical rationale: 
1. The use of a prophylactic antimicrobial lock solution may be advisable in 
patients with long term CVCs and a clinical record of multiple CRBSIs, despite 
total adherence to the aseptic technique.
81,82
 
2. Anticoagulant therapy should not be routinely used to decrease the risk of 
CRBSIs, even though it may reduce the risk of catheter-related thrombosis.
83
 
 
The role of impregnated CVCs 
Among strategies to prevent microbial cell attachment in a more effective way, CVCs 
impregnated with antiseptics and antibiotics have been proposed. However, the 
reduction of the infection rate was achieved with variable success and toxicity: 
1. Catheters impregnated with chlorhexidine-silver sulfadiazine can be effective in 
reducing colonization and infection,
84
 but hypersensitivity reactions have been 
documented.
85
 Although these are more expensive than standard catheters, the 
use of chlorhexidine-silver sulfadiazine catheters may lead to cost savings 
whenever the risk for CRBSIs is high and no success has been achieved with 
other preventive strategies, such as maximal barrier precautions and aseptic 
techniques. 
2. Catheters impregnated with minocycline and rifampin decreased significantly 
the incidence of CRBSIs,
86
 even though some concern may still exist regarding 
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the development of antimicrobial resistance.
87
 Its use may be cost effective if 
other preventive measures fail to control the incidence of CRBSIs. 
3. Silver-impregnated catheters are not associated with a lower rate of colonization 
or infection when compared to standard CVCs.
88
 
 
Novel strategies for prevention of CRBSIs 
A large number of approaches targeting the different stages of biofilm formation are 
currently in study:  
 silver nanoparticles display good antimicrobial activity and may allow a 
constant supply of Ag
+
 ions at the coated surface;
89
  
 phages displaying bactericidal activity can be used in the local control of 
biofilms;
90
  
 peptides, such as β-defensins, are a potential new class of antimicrobial agents 
with a broad activity spectrum and a relative selectivity towards microbial 
membranes;
91
  
 enzymes targeting EPS, namely dispersin B and N-acetyl-L-cysteine, are able to 
reduce bacterial adhesion and, furthermore, to disrupt and detach mature 
biofilms;
92,93
 
 drug delivery carrier systems, such as liposomes, polymeric microspheres, 
micelles and hydrogel-type materials may target matrix or biofilm bacteria by 
specific attachment and release of drugs in close vicinity of microorganisms;
94
  
 nitric oxide is an hydrophobic free-radical gas that may be impregnated in 
medical devices, showing antibacterial properties;
95,96
 
 electrical current may be used against biofilms either by prolonged exposure to 
low intensity direct electrical current (electricidal effect) or by enhancement of 
the activity of antimicrobials (bioelectric effect);
97,98
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 ultrasound has been demonstrated to enhance the activity of antimicrobial agents 
by inducing cavitation within the biofilm (bioacustic effect);
99
 
 light-activated antimicrobial agents generate reactive oxygen species when 
excited with the appropriate wavelength light, which are toxic to 
microorganisms growing on the surface of medical devices.
100,101
 
However, concerns about biosafety, microbial resistance and cost-effectiveness of such 
approaches still remain to be clarified.
102-104
 
 
Concerning other alternatives, biocompatible and inexpensive compounds 
already available may help to prevent microbial colonization. Cerium (
58
Ce) is the most 
abundant of the rare earth elements and belongs to the lanthanide group. It is extracted 
from minerals such as monazite and bastnaesite. Cerium has no known physiological 
role and does not penetrate mammalian cell membranes; however, it may form salts of 
medical interest. Cerium nitrate (Figure 1), by itself or in combination with silver 
sulphadiazine, has been extensively used in the management of burns, with a reduction 
in patient morbidity and mortality.
105
 In spite of the assumed reversion of the post-burn 
cell-mediated immunosuppression, its antimicrobial properties and mechanism of action 
still remain controversial and yet unexplained.
105,106
 Nevertheless, the uptake of cerium 
into the cytoplasm of microbial cells was described to inhibit cellular respiration, 
glucose metabolism or to disrupt the cell membrane.
107
 
 
 
 
Figure 1. Structure of cerium(III) nitrate hexahydrate. 
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Chitosans are hydrophilic polyaminosaccharides obtained by N-deacetylation of 
the crustacean chitin. Considerable attention has been dedicated by the pharmaceutical, 
food and cosmetic industries to these nontoxic and biocompatible polymers. In the 
medical field, chitosans are being investigated regarding its immunomodulating, 
antitumoral and antioxidant properties.
108,109
 In addition, chitosans exhibit a broad 
spectrum antimicrobial activity that is dependent on molecular weight, degree of 
deacetylation and type of substitution. High molecular weight chitosans cannot cross 
through cell membranes, forming a film because of its viscosity. In contrast, low 
molecular weight chitosans (LMWCs) can enter into the cell, being more amenable for a 
wide variety of biomedical applications due to its higher solubility in water (Figure 2). 
Hence, the mechanism of action of chitosans may be explained by: (1) external barrier 
formation and metal chelation with inhibition of microbial growth; (2) interaction 
between cationic chitosan derivatives and anionic microbial surface, resulting in cell 
wall leakage; (3) binding with teichoic acid and extraction of membrane lipids and (4) 
interference with mRNA and protein synthesis after nucleic penetration.
110,111
 
 
 
 
Figure 2. Structure of low molecular weight chitosan. 
 
Hamamelitannin is a natural compound found mainly in the bark and leaves of 
Hamamelis virginiana (witch hazel), indigenous to the woods of the Atlantic coast of 
North America and scarcely cultivated in Europe. It belongs to the family of tannins, 
which are plant polyphenols. Hamamelitannin is the ester of D-hamamelose (2-
hydroxymethyl-D-ribose) with two molecules of gallic acid, each containing three 
phenolic functional groups (Figure 3). Although scientific data supporting consistent 
efficacy are still limited, patients currently use hamamelis preparations in eye cleansing 
and in the treatment of eczema, varicose vein symptoms and minor inflammation of the 
skin and oral cavity.
112
 Hamamelis distillate may promote wound healing via anti-
17 
 
inflammatory effects.
113
 Furthermore, hamamelitannin inhibits tumor necrosis factor α-
mediated endothelial cell death,
114
 protects against cell damage induced by peroxides
115
 
or UVB radiation,
116
 while it suppresses staphylococcal infections in vivo (including 
methicillin-resistant S. aureus and S. epidermidis) by inhibiting the quorum sensing 
system of such bacteria.
117
 
 
 
Figure 3. Structure of hamamelitannin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
 
 
 
Study aims 
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This investigation has three main goals: 
1- To determine the aetiology of CVC colonization among intensive care patients 
at a national University Hospital.  Attending to the ecological niches occupied 
by the distinct microbial agents and to the patterns of antibiotic susceptibility 
found, the selection of preventive attitudes aiming to reduce CVC colonization 
in this hospital is also to be expected. 
2- To study in vitro biofilm formation by different organisms (S. epidermidis, S. 
aureus, A. baumannii and C. albicans), commonly associated to CVC 
colonization and CRBSI, at the surface of cerium, chitosan and hamamelitannin 
treated polyurethane catheters. 
3- To evaluate the in vivo efficacy of cerium, chitosan and hamamelitannin in the 
prevention of biofilm formation by S. epidermidis, S. aureus, A. baumannii and 
C. albicans on treated polyurethane catheter segments, using a mouse foreign 
body infection model.  The validation of this model to study CRBSI is also to be 
expected. 
Such goals were addressed according to the three tasks that follow. 
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Task 1 
Aetiology of CVC colonization 
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Materials and methods 
Study population 
A retrospective study of the clinical and laboratorial data base of Hospital de S. João, 
Porto, was performed. A 12-month period (from 1
st
 January to 31
st
 December, 2007) 
was considered. The results were collected from all the ICUs in this Hospital, 
corresponding to 2 General ICUs, 1 Neurocritical ICU, 1 Infectious Diseases ICU and 1 
Burn Unit, totalizing 45 beds. All positive results from the culture of the tips of CVCs 
were taken into account. 
 
Definitions 
Positive results from culture of CVC tips were assumed as CVC colonization since no 
data from associated blood infection neither the number of days of catheterization could 
be consistently recovered from the data source. 
 
Microbial characterization 
Microorganisms were isolated after removal of the CVCs from patients and culture of 
its distal tips, using the semiquantitative roll plate method described by Maki et al.
118
 
Whenever more than 15 colonies were visualised, the isolates were characterized and 
identified using the appropriate Vitek identification cards (bioMérieux, Paris, France), 
with the exception of fungal colonies (every colony was identified). Staphylococci were 
identified and tested for antimicrobial susceptibility with Vitek GP and GP-549 cards, 
respectively; Enterobacteriaceae and A. baumannii, with Vitek GN and GN-037 cards; 
P. aeruginosa, with Vitek GN and GN-022 cards. Candida isolates were characterized 
with Vitek 2 identification cards or API 20C galleries. Susceptibility testing to 
fluconazole, voriconazole, posaconazole, amphotericin B and caspofungin was assessed 
accordingly to the CLSI protocol M27-A3. 
 
Results 
Globally, from 1482 CVC distal tips recovered from ICU patients, 647 were found to be 
positive during the study period. The microorganisms found are listed in Table 1. 
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Table 1. Microbial isolates from CVC tips. 
 
Gram-positive cocci n % 
   
Staphylococcus epidermidis 260 40.2 
Staphylococcus aureus 83 12.8 
Staphylococcus haemolyticus 41 6.3 
Enterococcus faecalis 24 3.7 
Staphylococcus hominis 22 3.4 
Other coagulase-negative staphylococci 19 2.9 
Staphylococcus capitis 7 1.1 
Enterococcus faecium 7 1.1 
Staphylococcus warneri 4 0.62 
Kocuria kristinae 4 0.62 
Streptococcus sanguis 1 0.15 
Streptococcus pneumoniae 1 0.15 
Streptococcus agalactiae 1 0.15 
Staphylococcus simulans 1 0.15 
  
Total 475 73.4 
   
Gram-negative bacilli n % 
   
Pseudomonas aeruginosa 40 6.2 
Acinetobacter baumannii 18 2.8 
Proteus mirabilis 12 1.9 
Escherichia coli 11 1.7 
Klebsiella pneumoniae 10 1.5 
Enterobacter cloacae 8 1.2 
Morganella morganii 6 0.93 
Stenotrophomonas maltophilia 4 0.62 
Enterobacter aerogenes 3 0.46 
Serratia marcescens 3 0.46 
Burkholderia cepacia 2 0.31 
Other Klebsiella species 1 0.15 
Klebsiella oxytoca 1 0.15 
Citrobacter braakii 1 0.15 
  
Total 120 18.5 
   
Gram-positive bacilli n % 
   
Corynebacterium species 6 0.93 
Corynebacterium jeikeium 1 0.15 
  
Total 7 1.1 
23 
 
   
Yeasts n % 
   
Candida albicans 32 4.9 
Candida glabrata 6 0.93 
Candida tropicalis 4 0.62 
Candida parapsilosis 3 0.46 
  
Total 45 7.0 
  
The antibacterial susceptibility pattern of gram-positive cocci and gram-negative bacilli 
is detailed in Tables 2 and 3, respectively, for the most commonly tested and prescribed 
drugs in Hospital de S. João. The antifungal susceptibility pattern of Candida isolates is 
detailed in Table 4. 
 
 
Table 2. Antimicrobial susceptibility of gram-positive cocci. S, susceptible; R, resistant; I, intermediate. 
 
  Coagulase-negative staphylococci  Staphylococcus aureus 
  S  R  I  S  R  I 
Antibacterial agents  n %  n %  n %  n %  n %  N % 
Linezolid  288 100        55 100       
Oxacillin  42 14.7  243 85.3     11 20  44 80    
Teicoplanin  271 94.4     16 5.6  54 98.2     1 1.8 
Vancomycin  287 99.7     1 0.3  55 100       
                   
  Enterococcus faecalis  Enterococcus faecium 
  S  R  I  S  R  I 
  n %  n %  n %  n %  n %  N % 
Ampicillin  12 100           7 100    
Linezolid  12 92.3     1 7.7  7 100       
Penicillin  12 92.3  1 7.7        7 100    
Quinupristin/Dalfopristin      5 100     2 100       
Teicoplanin  12 92.3  1 7.7     2 28.6  5 71.4    
Vancomycin  12 92.3  1 7.7     1 14.3  6 85.7    
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Table 3. Antimicrobial susceptibility of gram-negative bacilli. 
 
  Enterobacteriaceae  Pseudomonas aeruginosa  Acinetobacter baumannii 
  S  R  I  S  R  I  S  R  I 
Antibacterial agents  n %  n %  n %  N %  n %  n %  n %  N %  n % 
Amikacin  29 80.6     7 19.4  16 69.6  7 30.4     17 94.4  1 5.6    
Cefepime  2 100        11 50  7 31.8  4 18.2          
Cefotaxime  34 97.1  1 2.9        1 100        18 100    
Ceftazidime  3 100        10 43.5  12 52.2  1 4.3  1 5.6  17 94.4    
Cefoxitine  3 100                         
Cefuroxime  27 79.4  7 20.6        1 100        18 100    
Ciprofloxacin  4 100        12 52.2  5 21.7  6 26.1  1 5.6  17 94.4    
Colistin  1 100        21 95.5  1 4.5     13 100       
Gentamicin  33 94.3  2 5.7     11 47.8  9 39.1  3 13  16 88.9  2 11.1    
Imipenem  33 91.7  3 8.3     7 30.4  15 65.2  1 4.3  1 5.6  17 94.4    
Levofloxacin  4 100        1 100        1 9.1  9 81.8  1 9.1 
Meropenem  36 100        9 39.1  8 34.8  6 26.1  1 5.6  17 94.4    
Piperacillin     2 66.7  1 33.3  18 78.3  4 17.4  1 4.3  1 5.6  17 94.4    
Piperacillin/Tazob.  29 80.6  2 5.6  5 13.9  9 69.2  3 23.1  1 7.7     17 100    
Tobramycin  1 100        13 59.1  9 40.9             
 
 
Table 4. Antifungal susceptibility of Candida isolates. 
 
  C. albicans  C. glabrata  C. parapsilosis 
  S  R  I  S  R  I  S  R  I 
Antifungal agents  n %  n %  n %  n %  n %  n %  n %  n %  n % 
Fluconazole  27 100        5 100        2 66.7     1 33.3 
Voriconazole  27 100        5 100        3 100       
Posaconazole  27 100        5 100        3 100       
Amphotericin B  27 100        5 100        3 100       
Caspofungin  27 100        5 100        3 100       
 
 
Discussion 
Taken globally, the epidemiological data concerning the aetiology of CVC colonization 
in the ICUs under evaluation was similar to previous publications. Although catheter 
colonization does not invariably lead to CRBSI, it usually represents its initial step. 
As expected, coagulase-negative staphylococci (n=354; 54.7%), mainly S. 
epidermidis (40.2%), were the most frequent species isolated from CVC tips. S. aureus 
(12.8%) was the second most common organism. These microbial agents are thought to 
gain access to distal tips of CVCs by contiguous spread from the patient skin and 
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mucous membranes along the external surface of catheters or, intraluminally, from 
contamination of catheter hubs. High susceptibility levels to linezolid, teicoplanin and 
vancomycin were found for these cocci. However, methicillin resistance among S. 
aureus (80%) and coagulase-negative staphylococci (85.3%) was higher than expected 
from similar ICU data (55.3% and 75%, respectively) which, by itself, is associated 
with an increased length of hospitalization, cost and mortality.
119
 
Enterococcus faecalis (3.7%) and Enterococcus faecium (1.1%) were the next 
most common gram-positive cocci, following staphylococci. These enteric bacteria are 
found mainly in the intestinal tract of patients. Besides skin contamination with bowel 
microorganisms during daily hygiene care, such organisms most probably reach CVC 
hubs through the hands of hospital personnel. Although a small number of enterococci 
have been tested in this study, E. faecalis displayed high susceptibility to penicillin, 
ampicilin, linezolid, teicoplanin and vancomycin; as expected, quinupristin/dalfopristin 
lacks activity against this species; conversely, both isolates of E. faecium tested were 
susceptible. The single other antibacterial with activity against E. faecium was linezolid; 
high resistance levels were found to vancomycin and teicoplanin. As there is a global 
concern about conjugated transfer of the vanA gene from enterococci to S. aureus,
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routine surveillance for resistance patterns of such organisms is of paramount 
importance. 
Among gram-negative bacilli, Enterobacteriaceae (n=56; 8.6%), P. aeruginosa 
(6.2%) and A. baumannii (2.8%) predominated. Enterobacteriaceae, as part of normal 
intestinal flora, may contaminate indwelling devices during hygiene care, similarly to 
what was described for enterococci. Except for cefuroxime, a second-generation 
cephalosporin, Enterobacteriaceae demonstrated high susceptibility to the other tested 
cephalosporins, which seems to exclude this hospital from the international trend 
towards third and fourth-generation cephalosporin resistance.
121
 Carbapenems also 
showed good activity against Enterobacteriaceae. 
P. aeruginosa is frequently a HCRI organism that thrives in moist environments. 
It may assume a pathogenic pattern of behaviour whenever the mucous membranes or 
the skin are disrupted, as is the case with central venous catheterization. Since P. 
aeruginosa often displays MDR, it may become dominant when more susceptible 
bacteria belonging to the indigenous microbial population are suppressed, as usually 
happens in the ICU setting. Among Pseudomonas isolates, resistance levels found to 
meropenem (34.8%) and imipenem (65.2%) were unexpectedly high, as was also the 
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case for ceftazidime (52.2%) and tobramycin (40.9%).
122
 Drug resistance to piperacillin 
(17.4%), ciprofloxacin (21.7%), gentamicin (39.1%) and amikacin (30.4%) was in 
accordance with international data. Colistin showed excellent activity against P. 
aeruginosa. 
A. baumannii may colonize extensively the hospital environment. Occasionally, 
it can be found on human skin, mucous membranes and secretions as a saprophyte. 
Whenever it causes HCRIs, A. baumannii is often associated with medical indwelling 
devices such as endotracheal tubes or CVCs and is highly resistant to antimicrobial 
agents.
121,123
 Invariably, the most disturbing fact in the isolated strains was an extremely 
high resistance level to carbapenems (94.4%). Susceptibility was found only to 
gentamicin (88.9%), amikacin (94.4%) and colistin (100%). Moreover, A. baumannii 
has been responsible for the closure of some of the aforementioned ICUs, for several 
days, in order to hygienize and eradicate the organism from the environment, as it is 
highly transmissible during an outbreak. Besides the additional costs, the inconvenience 
and medical risk of patient transfer to other hospital ICUs during these periods must be 
taken into account. 
The yeast most frequently recovered from CVCs was C. albicans (4.9%), at the 
fourth position of the ranking of agents, in conformity with literature. Candida spp are 
the most common opportunistic fungal pathogens. They usually colonize the human 
skin, mucous membranes and gastrointestinal tract and may cause fungemia following 
intestinal wall translocation or contamination of vascular catheters. Against expectations 
from European data, C. glabrata (0.93%) was second to C. albicans.
25
 No remarkable 
levels of resistance were found among Candida spp; in fact, all strains were susceptible 
to fluconazole, voriconazole, posaconazole, amphotericin B and caspofungin. This 
might be explained by the limited exposure to antifungal agents in this hospital. 
Continued surveillance on species distribution and antifungal susceptibility profile is 
needed, since a low number of Candida isolates was tested. 
A problem often arising in the interpretation of positive catheter segment 
cultures is the false positivity that may result from adhesion of skin organisms to CVC 
during its removal. Such finding may be responsible particularly for cases attributed to 
coagulase-negative staphylococci. Conversely, the roll plate method may be inadequate 
for the recovery of organisms from the intraluminal portion of catheter segments, 
underestimating its colonization and, therefore, leading to false negative results. 
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All the described organisms share the capacity to form biofilm on indwelling 
devices. Sessile cells in such a matrix exhibit a promoted ability to colonize catheters 
and overcome the host immune system response as well as the effects of antimicrobial 
drugs in circulation, comparing to their planktonic counterparts, from which they are 
phenotypically distinct. 
 Regarding that the microbial agents most frequently isolated are usual 
patient colonizers or hospital environmental contaminants, it seems to be a clear benefit 
to promote the aforementioned essential elements of CVC use in this hospital, in order 
to reduce CRBSIs. Furthermore, the design of therapeutic protocols based on the local 
patterns of antimicrobial susceptibility might help to pursue a more strict selection of 
antimicrobials. As a policy to control the undesired high levels of resistance found, 
rotational antimicrobial use could be highly advisable.
124-127
 
While new approaches to estimate the true incidence of CVC related infections 
are needed, devoted attention to measures aiming the reduction or the complete 
blockade of its colonization is mandatory, particularly in the ICU setting. 
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Task 2 
In vitro biofilm formation on treated catheters 
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Materials and methods 
Chemicals 
Cerium nitrate [cerium(III) nitrate hexahydrate, Sigma-Aldrich], chitosan [low-
molecular-weight chitosan 107 kDa, 75-85% deacylated; Sigma-Aldrich; stock solution 
of 4% (w/v) prepared in 1% acetic acid, pH 4.0] and hamamelitannin 
[hamamelofuranose 2′,5-digallate, 2-C-(Hydroxymethyl)-D-ribofuranose 2′,5-digallate; 
Sigma-Aldrich] were used in the experiments. 
 
Microbial strains 
A type strain from the American Type Culture Collections (ATCC) and a clinical isolate 
of each of four microbial species were used: the type strains were S. aureus ATCC 
29213, S. epidermidis ATCC 155, A. baumannii ATCC 19606 and C. albicans ATCC 
90028; the clinical strains of S. aureus (SA1), S. epidermidis (SE1), A. baumannii 
(AB1) and C. albicans (CA1) had been previously isolated from cultures of CVCs 
removed from critical care patients admitted at Hospital S. João, Porto, Portugal. All 
clinical isolates had been identified by Vitek system (bioMérieux, Vercieux, France). 
Bacterial strains were kept frozen in Luria-Bertani broth (LB; Difco 
Laboratories, Detroit, MI, USA) supplemented with 20% glycerol and the yeast strains 
in yeast potato dextrose medium (YPD; Difco Laboratories) supplemented with 40% 
glycerol at -70ºC until testing. For each experiment, the microorganisms were 
subcultured twice on LB agar, 37ºC, 24 h for bacteria or Sabouraud agar, 35ºC, 24 h 
(Difco Laboratories) for yeasts to assess the purity of the culture and its viability. 
 
Antimicrobial activity 
The minimal inhibitory concentration (MIC) of cerium nitrate, LMWC and 
hamamelitannin was evaluated accordingly to the Clinical and Laboratory Standards 
Institute (CLSI) microdilution reference protocol M07-A8 for bacterial strains and 
protocol M27-A3 for yeast strains. The tested concentrations ranged from 5.4x10
3
 to 
3.3x10
2
 mg/L for cerium nitrate, 1.0x10
4
 to 1.6x10
2
 mg/L for LMWC and 100 to 10 
mg/L for hamamelitannin. MIC end point was defined as the lowest drug concentration 
that completely inhibited the growth of microorganisms in microdilution wells. 
To determine the minimal lethal concentration (MLC), 20 µL from each 
microdilution well were plated in LB agar (for bacteria) or Sabouraud agar (for yeasts). 
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The plates were incubated at 37ºC for 24 h (bacterial strains) or 35ºC for 48 h (yeast 
strains) with subsequent enumeration of colony forming units. MLC was defined as the 
lowest drug concentration that killed at least 99.9% of the final inoculum. 
Furthermore, to study the effect of cerium nitrate against C. albicans, flow 
cytometric analysis was performed with two fluorescent markers: FUN-1 (to evaluate 
cell metabolic activity) and propidium iodide (PI; a marker of cell death that only 
penetrates cells with severe membrane lesions).
128
 After cerium nitrate treatment, yeasts 
were collected, washed twice in distilled water and resuspended in FUN-1 0.5 μM or PI 
1 μM. The yeast suspensions were incubated for 30 min at 37ºC in the dark; following 
incubation, the suspensions were centrifuged and the supernatant transferred to flow 
cytometry propylene tubes. As controls for FUN-1 staining, untreated cell suspensions 
and cells treated with 1 mM sodium azide (Sigma) for 1 h and stained under the same 
conditions were used. Controls for PI staining included suspensions of untreated and 
killed cells (90ºC for 30 min), stained with PI under the same conditions. For each 
experimental condition, 20,000 events were analysed in a standard flow cytometer 
(FACSCalibur BD Biosciences, Sydney) with three PMTs equipped with standard 
filters (FL1: BP 530/30 nm; FL2: BP 585/42 nm; FL3: LP 670 nm), a 15 mW 488 
Argon Laser and operating with Quest Pro software (version 4.0.2, BD Biosciences, 
Sydney). Results were expressed as a staining index (SI) for FUN-1, defined as the ratio 
between the mean fluorescence of treated cell suspensions and the corresponding value 
for the non-treated cells at FL2 (values ≥ 1 represent treatment effect) and, for PI, as the 
percentage of positive cells showing high fluorescence at FL3.
128
 
 
Biofilm formation on polyurethane catheters 
The microbial strains were grown overnight in LB broth at 37ºC and 180 rpm, for 
bacteria, or Sabouraud broth at 35ºC and 180 rpm, for yeasts. Cells were harvested by 
centrifugation (10000 g, 5 min), washed with phosphate buffered saline (PBS), counted 
in a Newbauer chamber and standardized to 1x10
7
 cells/mL in LB broth for bacteria and 
1x10
6
 cells/mL in RPMI (Sigma-Aldrich) for yeasts. The anti-biofilm effect of the 3 
different test compounds was evaluated in the presence of four concentrations of cerium 
nitrate (1.7x10
3
, 1.3x10
3
, 6.5x10
2
 and 3.3x10
2
 mg/L) and three of hamamelitannin (100, 
80 and 50 mg/L); regarding LMWC, concentrations tested corresponded to 625, 160 
and 78 mg/L for bacteria and 1.0x10
4
, 5.0x10
3
 and 625 mg/L for yeasts. One single 
fragment of polyurethane intravenous catheters (BD VialonTM 16G 1.7x45 mm), with 1 
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cm length, was placed in each well of 12-well microplates, containing 1 mL of the 
standardized microbial suspensions. 
After incubation (24 h for bacteria; 24 and 48 h for yeasts), at 37ºC, catheter 
fragments were removed, gently washed with PBS and placed in new microplates for 
biofilm quantification with 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide (XTT), as previously described 
129
. Briefly, 1 mL of the XTT solution 
was added to each well containing the CVC fragment with the prewashed biofilm and to 
control wells containing a sterile CVC fragment (for the measurement of background 
XTT reduction levels). The microplates were incubated for 5 h at 37ºC, in the dark. 
Finally, the optical density was measured at 492 nm. All the assays were performed in 
triplicate. 
 
Data analysis 
Biofilm metabolic activity in the presence of cerium nitrate, LMWC and 
hamamelitannin was expressed as the percentage in relation to the positive control. 
Values were divided by 1000 and arcsine square root transformed to achieve a normal 
distribution and homoscedasticity. For each compound, each concentration and each 
microorganism, biofilm formation was compared by one-way ANOVA, followed by a 
Dunnett's test to identify significant effects; p value <0.05 was considered significant. 
 
Results 
Antimicrobial activity 
Cerium nitrate MIC ranged between 3.3x10
2
 to 1.3x10
3
 mg/L for bacterial strains. For 
yeasts, concentrations up to 2.6x10
3
 mg/L were needed. Globally, MLC corresponded to 
the double or more the MIC values for all microbial species (Table 5). 
For LMWC, MICs ranged between 1.6x10
2
 and 3.1x10
2
 mg/L for all bacteria. A 
higher concentration (1.0x10
4
 mg/L) was needed to inhibit C. albicans growth. MLC 
values nearly doubled the MIC values for all bacterial species. MLC and MIC were 
similar for C. albicans (Table 5). 
Hamamelitannin produced no inhibition of microbial growth, at concentrations 
ranging between 10 to 100 mg/L. 
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Table 5. Minimal inhibitory concentration (MIC) and minimal lethal concentration (MLC) of cerium 
nitrate and low molecular weight chitosans (LMWC). 
 
 
 
MIC 
 
MLC 
 
Cerium nitrate 
(mg/L) 
 
LMWC 
 (mg/L) 
 
Cerium nitrate 
(mg/L) 
LMWC 
 (mg/L) 
 
Bacterial strains 
 
    
S. aureus (SA1) 3.3x10
2 
1.6x10
2
 5.4x10
3
 3.1x10
2
 
S. aureus ATCC 3.3x10
2
 1.6x10
2 2.6x103 1.25x103 
S. epidermidis (SE1) 1.3x10
3
 1.6x10
2
 2.6x10
3
 3.1x102 
S. epidermidis ATCC 6.5x10
2
 1.6x10
2 2.6x103 6.3x102 
A. baumannii (AB1) 1.3x10
3
 1.6x10
2 5.4x103 2.5x103 
A. baumannii ATCC 1.3x103 3.1x102 5.4x103 1.25x103 
 
Yeast strains 
 
    
C. albicans (CA1) 2.6x10
3
 1.0x10
4
 5.4x10
3
 1.0x10
4
 
C. albicans ATCC  2.6x10
3
 1.0x10
4
 5.4x10
3
 1.0x10
4
 
 
 Concerning flow cytometric studies, FUN-1 staining demonstrated that 
cerium nitrate impairs C. albicans metabolism and ultimately can lead to cell membrane 
damage: the MLC concentration caused a critical decrease in the cellular metabolism, 
starting approximately after 1.5 h of exposure and increasing along the time; PI was 
able to stain approximately 50% of the cells treated with the MLC after 6 h of 
incubation and, after 24 h of treatment, almost 85% of cells exhibited membrane injury. 
MIC concentration was unable to induce membrane damage. 
 
Biofilm formation on polyurethane catheters 
Cerium nitrate, at a concentration of 1.7x10
3
 mg/L, reduced the mean biofilm metabolic 
activity of C. albicans by 58.9% (±7.4) at 24 h and by 59.14% (±13.0) at 48 h. No 
relevant biofilm inhibition was found for bacterial strains with cerium nitrate at 
concentrations lower than MLC (Figure 4. A, B and C). 
LMWC, at a concentration of 78 mg/L, reduced the biofilm metabolic activity of 
S. epidermidis by 80.46% (±0.0) (Figure 4. D). At a concentration of 5.0x10
3
 mg/L, 
LMWC reduced C. albicans biofilm metabolic activity by 87.5% (±0.0) at 24 h and by 
90.06% (±0.0) at 48 h (Figure 4. F). However, inconsistent results were found with S. 
aureus and A. baumannii (Figure 4. D and E). 
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Hamamelitannin, at a concentration of 100 mg/L, decreased significantly the 
mean biofilm metabolic activity of S. aureus by 23.0% (±10.7%); of S. epidermidis by 
42.2% (±3.78%) and of A. baumannii by 31.8% (±0.88) (Figure 4. G and H). 
Inconclusive results were found with C. albicans strains, at 24 and 48 h (Figure 4. I). 
 
 
 
Figure 4. Effect of cerium nitrate (A, B and C), low molecular weight chitosan (D, E and F) and 
hamamelitannin (G, H and I) on biofilm formation (as percentage of the control) by Gram positive cocci, 
Gram negative bacteria and yeasts (at 24 and 48 h). Differences between control and antimicrobial groups 
were statistically significant (P < 0.01). 
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Discussion 
Indwelling medical devices are used for a wide array of purposes. Unfortunately, they 
are quite prone to colonization by biofilm producing microorganisms. New strategies 
aiming the blockade of such biofilms have been developed and although some are in use 
with variable success, there is still a wide field for further investigation. 
A review conducted by Garner et al., 2005, gathered information on the 
bacteriostatic effect of cerium nitrate against a panel of bacteria.
105
 Our study not only 
adds to this effect but also documents unequivocally the microbicidal effect of cerium 
nitrate against bacteria and yeasts. This might be quite useful in medical applications 
because toxicity is rare with lanthanides since they do not penetrate the membranes of 
living mammalian cells.  
Concerning microbial growth inhibition by cerium nitrate, our results indicate 
that MICs for S. aureus are similar to previous descriptions,
105
 while we determined for 
the first time MICs for S. epidermidis, A. baumannii and C. albicans. Furthermore, the 
so far unclear cerium nitrate microbicidal effect was documented and MLCs were 
established for major colonizers of indwelling medical devices. 
At lower concentrations, cerium nitrate was only effective against C. albicans 
biofilm, with no difference in its activity after 24 or 48 h of incubation. 
No further experiments were then pursued in order to clarify the mechanism by 
which cerium nitrate inhibited in a different way biofilm formation by bacteria and 
yeasts. 
The spectrum wideness of antimicrobial activity of chitosans depends on several 
factors, namely the molecular weight (MW).
108,109,111
 However, inconclusive data 
regarding the actual efficacy of high MW, low MW and oligochitosans is available. 
Nevertheless, LMWCs seem to exhibit a strong antibacterial activity (which was 
described to be higher against Gram positive bacteria as their molecular weight 
increases and against Gram negative bacteria as their molecular weight decreases) and, 
also, antifungal activity.
130,131
 
As far as antimicrobial activity is concerned, MICs and MLCs were determined 
for all tested microbial species. Although there is a tendency in literature to characterize 
chitosans as bacteriostatic and fungistatic, as stated by Goy et al., 2009, our results 
suggest unequivocally that LMWC 107 kDa exhibits a microbicidal effect (Table 5). 
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At subinhibitory concentrations, a significant reduction of the biofilm metabolic 
activity was only found for S. epidermidis and C. albicans. This might somewhat 
decrease the medical interest of LMWC use in the prevention of indwelling device 
colonization, although these two species are very relevant and frequent CVC colonizers. 
A lower degree of acetylation might improve LMWC antimicrobial effectiveness, but 
no further studies on this topic were conducted. 
Hamamelitannin produced no inhibition of microbial growth: no MICs or MLCs 
could be established at concentrations ranging between 10 to 100 mg/L, as expected. 
Regarding the experiments on polyurethane catheter segments, inhibition of the 
biofilm metabolic activity was found at a concentration of 100 mg/L for all tested 
bacteria. The inhibition of the quorum sensing system of Gram positive bacteria, such as 
S. aureus and S. epidermidis, had already been documented by Kiran et al., 2008. 
Interestingly, the biofilm inhibitory effect upon Gram negative bacteria such as A. 
baumannii was originally described by the present study. A. baumannii is a conspicuous 
pathogen usually related to MDR and invasive infections among critical care patients. It 
has been advocated that hamamelitannin might exhibit a better effect in vivo than in 
vitro.
117
 
 
At present, medical device colonization is a global threat that may contribute to 
antimicrobial resistance. The microbicidal effect of cerium nitrate and LMWC upon 
usual CVC colonizers was clearly demonstrated. Moreover, at lower concentrations, 
both were found to be fungistatic. Hamamelitannin inhibited the biofilm metabolic 
activity of all tested bacteria: for A. baumannii, this effect was an original description. 
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Task 3 
In vivo efficacy of treated catheters 
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Materials and methods 
Chemicals 
Cerium nitrate [cerium(III) nitrate hexahydrate, Sigma-Aldrich, Schnelldorf, Germany], 
chitosan [low-molecular-weight chitosan 107 kDa, 75-85% deacylated, Sigma-Aldrich, 
St. Quentin Fallavier, France; stock solution of 4% (w/v) prepared in 1% acetic acid, pH 
4.0] and hamamelitannin [hamamelofuranose 2′,5-digallate, 2-C-(Hydroxymethyl)-D-
ribofuranose 2′,5-digallate, Sigma-Aldrich, St. Quentin Fallavier, France] were used in 
the experiments. 
 
Microbial strains and inoculum preparation 
Four type strains from the American Type Culture Collection were used: 
Staphylococcus aureus ATCC 29213, Staphylococcus epidermidis ATCC 155, 
Acinetobacter baumannii ATCC 19606 and Candida albicans ATCC 90028. 
Bacterial strains were kept frozen in Luria-Bertani broth (LB; Difco 
Laboratories, Detroit, MI, USA) supplemented with 20% glycerol and yeast strains in 
yeast potato dextrose broth (YPD; Difco Laboratories) supplemented with 40% 
glycerol, at -70ºC until testing. For each experiment, the microorganisms were 
previously subcultured twice on LB agar at 37ºC during 24 h for bacteria or Sabouraud 
agar (Difco Laboratories) at 35ºC during 24 h for yeasts, in order to assess the viability 
and purity of the culture. 
For the inoculum preparation, the microbial strains were grown overnight in LB 
(bacteria) or Sabouraud broth (yeast) at 37ºC and 180 rpm; cells were harvested by 
centrifugation (10000 g, 10 min), washed with PBS, counted in a Newbauer chamber 
and the concentration was standardized to 1x10
7
 cells/mL for bacteria and 1x10
6
 
cells/mL for yeasts, in PBS. 
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Polyurethane catheter implantation procedure 
A mouse subcutaneous foreign body infection model as described by Rupp et al.
132
 was 
used, with slight modifications. Eight-week-old pathogen-free female BALB/c mice 
(Charles River) weighting 20 g were used. Animals were housed in accordance with the 
Federation of European Laboratory Animals of science Associations (FELASA) 
criteria. Animal experiments were approved by the Animal Ethical Committee of 
Faculty of Medicine, University of Porto. 
Prior to catheter implantation, mice were anaesthetized by intraperitoneal 
injection (1 mg/kg) of a mixture of xylazine (20 mg/mL) and ketamine (100 mg/mL) in 
a ratio of 1:2 (vol/vol) and the lower back of each animal was shaved with a hair clipper 
and disinfected with 0.5% chlorhexidine in 70% alcohol. A 2 mm incision was made 
longitudinally and the subcutis was dissected. Using an aseptic technique, six 1-cm 
segment polyurethane intravenous catheters (BD Vialon
TM
 16G 1.7x45 mm, Becton 
Dickinson and Company, Canada) were implanted into the subcutaneous space (Figure 
6. A). Before implantation, catheters were soaked for 24 h with cerium nitrate, 
hamamelitannin (Figure 5) or LMWC at concentrations corresponding to the respective 
(previously determined in task 2) minimal inhibitory concentration (MIC), ½ MIC and 
¼ MIC regarding each species. Catheters incubated in plain PBS were used as positive 
control. Five animals were used for each experimental condition. Thereafter, 300 µL of 
each standardized microbial suspension or of PBS (control) were injected into the 
pockets. The incision was closed with a monofilament suture and disinfected with 0.5% 
chlorhexidine in 70% alcohol (Figure 6. B).  
 
 
Figure 5. Catheter segments soaked with hamamelitannin before the implantation procedure. 
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Figure 6. Subcutaneous pocket with catheter segments after implantation in the mice (A) and after 
inoculation and closure of the pocket (B). 
 
Biofilm formation assessment 
At day 7, the animals were sacrificed, the catheters were aseptically removed (Figure 7. 
A and B) and biofilm was quantified spectrophotometrically by two different 
methodologies: XTT assay, measuring the biofilm metabolic activity at 492 nm, and 
crystal violet (CV) assay, measuring the biofilm total biomass at 590 nm.
133
 In addition, 
catheter segments were submitted to scanning electron microscopy (SEM) imaging.
 
 
   
Figure 7. Mice at day 7 of subcutaneous pocket infection with A. baumannii: catheter segments treated 
with hamamelitannin (A) and without treatment (B). 
 
 
A B 
A B 
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Scanning electron microscopy 
Catheters were washed in PBS, sectioned lengthwise and fixed overnight (4% 
formaldehyde and 1% glutaraldehyde v/v in PBS). The samples were rinsed in PBS and 
air dried in desiccators.
134
 Samples were coated with gold/palladium (40%/60%) and 
observed in a scanning electron microscope (JEOL JSM 6301F/Oxford INCA Energy 
350) in high vacuum mode at 15 kV, at CEMUP (Materials Centre of the University of 
Porto). 
 
Data analysis 
Biofilm metabolic activity and total biomass formed in the presence of cerium nitrate, 
LMWC and hamamelitannin were expressed as the percentage in relation to the control. 
Values were divided by 1000 and arcsine square root transformed to achieve normal 
distribution and homoscedasticity. For each compound, each concentration and each 
microorganism, biofilm formation was compared by one-way ANOVA, followed by a 
Dunnett's test to identify significant effects; P value< 0.05 was considered significant. 
 
Results 
Cerium nitrate, at a concentration of 6.5x10
2
 mg/L, reduced significantly the biofilm 
metabolic activity of S. epidermidis by 48.3% (±12.4) and its total biomass by 37.0% 
(±8.9) (Figure 8. A). For C. albicans, cerium nitrate at 1.3x10
3
 mg/L inhibited the 
metabolic activity by 66.4% (±7.7) and the biomass by 28.0% (±4.3) (Figure 8. B). 
 LMWC, at 80 mg/L, decreased significantly the biofilm metabolic activity of 
S. epidermidis by 57.6% (±14.3) and its total biomass by 41.3% (±5.6) (Figure 8. C). 
Concerning C. albicans, 2.5x10
3
 mg/L resulted in inhibition of the metabolic activity by 
43.5% (±16.6) and of the total biomass by 23.2% (±13.7) (Figure 8. D). 
Hamamelitannin reduced significantly all bacterial biofilms at subinhibitory 
concentrations: at 50 mg/L, S. aureus biofilm metabolic activity decreased by 59.3% 
(±19.1) and its total biomass by 48.4% (±8.0) (Figure 8. E); at the same concentration, 
S. epidermidis biofilm metabolic activity was reduced by 36.3% (±12.4) and its total 
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biomass by 34.6% (±6.9) (Figure 8. F); at 30 mg/L, hamamelitannin inhibited A. 
baumannii biofilm metabolic activity by 36.7% (±3.4) and its total biomass by 31.6% 
(±9.2) (Figure 8. G).  
At other subinhibitory concentrations, no significant biofilm inhibition was 
found for the tested microbial strains (data not shown). 
 
 
 
Figure 8. Effect of cerium nitrate (A and B), low molecular weight chitosan (LMWC) (C and D) and 
hamamelitannin (E, F and G) upon biofilm formation by S. epidermidis (A, C and F), S. aureus (E), A. 
baumannii (G) and C. albicans (B and D). XTT assay was used to determine the biofilm metabolic 
activity and CV assay to measure the total biomass. (*) P value <0.05. 
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Scanning electron microscopic examination was used to determine the 
architectural differences between biofilms. Untreated biofilms (Figure 9. A, B, I, J, M, 
N, Q and R) comprised a more dense network of microbial cells and exopolymeric 
matrix than treated biofilms (Figure 9. C to H, K, L, O, P and S to V). 
 
Figure 9. Scanning electron microscopic (SEM) examination of untreated biofilms of S. epidermidis (A 
and B), S. aureus (I and J), A. baumannii (M and N) and C. albicans (Q and R). SEM examination of S. 
epidermidis biofilms treated with cerium nitrate at 6.5x10
2
 mg/L (C and D), LMWC at 80 mg/L (E and F) 
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and hamamelitannin at 50 mg/L (G and H); S. aureus biofilms treated with hamamelitannin at 50 mg/L 
(K and L); A. baumannii biofilms treated with hamamelitannin at 30 mg/L (O and P); C. albicans 
biofilms treated with cerium nitrate at 1.3x10
3
 mg/L (S and T) and LMWC at 2.5x10
3
 mg/L (U and V). 
 
Discussion 
In the long quest aiming to prevent medical device-related infections in a more effective 
way, many different strategies have been proposed. Until now, such objective remains 
to be fulfilled. Cerium nitrate, LMWC and hamamelitannin are biocompatible and 
relatively inexpensive compounds that could be used to coat CVCs and other medical 
indwelling devices. Differences in their mechanisms of action might explain the pattern 
of antimicrobial activity: whereas cerium nitrate and LMWC may disrupt the cell 
membrane,
105,111
 hamamelitannin seems to inhibit bacterial cell communication.
117
 The 
microbicidal effect of cerium nitrate and LMWC upon usual CVC colonizers was 
previously shown in vitro, as was the antibiofilm activity of hamamelitannin on 
polyurethane catheter segments. However, in vivo experiments with subinhibitory 
concentrations of those compounds remained to be made, since results obtained under in 
vitro conditions do not account for the intricate interaction between the host cells, 
immune system and biofilm community. 
 Garner et al., studying the action of cerium nitrate on the treatment of severe 
burns, reported about its limited antimicrobial properties.
105
 However, minimal lethal 
concentrations (MLCs) and MICs have been published more recently both for bacteria 
and yeasts.
135
 In vivo, at subinhibitory concentrations, cerium nitrate exhibited an 
antibiofilm effect only against C. albicans. Such selective finding should not preclude 
its biomedical use since it is used routinely in medical burn wound care as an effective 
antiseptic, at much higher concentrations and with no known toxicity. In addition, 
Candida organisms are important pathogens regarding CRBSIs. 
 The microbicidal activity of LMWC upon usual CVC colonizers has already 
been documented in vitro. More recently, using an in vivo CVC model, Martinez et al. 
demonstrated the efficacy of chitosan against Candida species biofilms.
136
 Our study 
not only supports these findings concerning C. albicans, at subinhibitory concentrations 
of chitosan, but further documents the antibiofilm efficacy against S. epidermidis, a 
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much more common CVC colonizer.
69
 Given the known biocompatibility of chitosan, 
promising results could be achieved in the prevention of CRBSIs by a wider range of 
microbial colonizers if higher concentrations were used for treating the surface of 
CVCs. 
At subinhibitory concentrations, the highest antibiofilm efficacy was obtained 
with hamamelitannin: a reduction in the metabolic activity and total biomass was 
documented for S. aureus, S. epidermidis and A. baumannii. This is the first report of in 
vivo biofilm inhibition for A. baumannii, confirming our previous in vitro description. 
Moreover, the antibiofilm efficacy was achieved at lower concentrations than expected 
considering our in vitro results regarding all tested bacteria, a fact that may be 
attributable to differences in environmental conditions. Concerning staphylococci, 
Kiran et al. attributed such discrepancy to the specific in vivo quorum-sensing inhibitor 
effect of hamamelitannin.
117
 For pre-soaked grafts, the same authors reported no signs 
of staphylococcal infection in vivo with hamamelitannin concentrations of 30 mg/L, but 
the present study found a statistically significant reduction of biofilm formation by no 
more than ~50%, even at 100 mg/L. Nonetheless, hamamelitannin may be an excellent 
compound to coat medical devices given its bacterial range of biofilm inhibition. 
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Aetiology of CVC colonization (paper I) 
 The aetiology of CVC isolates recovered from national ICU patients was similar 
to European data except for C. glabrata, which ranked second among yeasts. 
 Antimicrobial resistance was higher than expected, particularly regarding S. 
epidermidis, S. aureus, E. faecium, P. aeruginosa and A. baumannii. 
Conversely, Enterobacteriaceae were highly susceptible to cephalosporins. No 
antifungal resistance was found among the tested yeast strains. 
 In order to ensure the efficacy of new therapeutic protocols considering the local 
patterns of antimicrobial susceptibility, continued surveillance of antimicrobial 
resistance is of paramount importance. 
 The promotion of the essential elements of CVC care in this hospital is expected 
to result in a reduction of CRBSIs. 
 
In vitro microbial biofilm formation on chemically treated catheters (papers II, IV-
VIII) 
 Despite the controversy that could be found in previous published studies, 
cerium nitrate and LMWC displayed an effective microbicidal effect upon S. 
epidermidis, S. aureus, A. baumannii and C. albicans. 
 In the case of C. albicans, such effect of cerium nitrate is related to cell 
membrane damage. 
 At subinhibitory concentrations: 
o Catheters treated with cerium nitrate were effective against C. albicans 
biofilm formation; 
o Catheters treated with LMWC inhibited S. epidermidis and C. albicans 
biofilm formation; 
o Catheters treated with hamamelitannin inhibited biofilm formation by all 
the tested bacteria. 
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In vivo efficacy of chemically treated catheters (paper III) 
 The in vivo antibiofilm efficacy of catheters treated with cerium nitrate, LMWC 
and hamamelitannin was found to be similar to that documented in vitro, notably 
regarding A. baumannii. 
 The mouse foreign body infection model with subcutaneous implantation of 
catheter segments was documented to be a useful model for the study of 
indwelling catheter infection, both by quantitative and qualitative methods such 
as electron microscopy imaging studies. 
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Future perspectives 
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A more durable coating strategy for cerium nitrate, chitosan and hamamelitannin and its 
further in vivo testing using the CVC animal model is the next step in the path to 
develop a more cost-effective and biocompatible indwelling catheter, that could reduce 
CRBSIs more effectively than the present available options. 
In addition, studies are being conducted to clarify the mechanism of biofilm 
inhibition and the endovascular biocompatibility of these inhibitors, which may play 
promising roles in future biomedical applications. 
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Patients admitted at Intensive Care Units (ICUs) often require central venous catheters 
(CVCs) for multiple purposes. However, infectious complications may follow, ranging 
from simple catheter colonization to sepsis. Worldwide, the incidence rate of catheter-
related bloodstream infections (CRBSIs) is high and its socio-economic impact is 
considerable. Staphylococcus epidermidis, Staphylococcus aureus, Acinetobacter 
baumannii and Candida albicans are among microbial agents most frequently isolated 
from CRBSIs. Whichever might be the route of contamination, these organisms usually 
form biofilm on CVCs that help to promote microbial resistance. Several strategies have 
been proposed to control biofilm formation, but the success in reducing the infection 
rate was achieved with variable success and toxicity. Concerning other alternatives, 
cerium nitrate, chitosan and hamamelitannin are biocompatible and inexpensive 
compounds with known antimicrobial activity (although not fully elucidated) that could 
help to reduce CRBSIs. 
The three main objectives of this investigation involved: (1) the determination of 
the aetiology of CVC colonization among intensive care patients at a national university 
hospital; (2) the study of in vitro biofilm formation by organisms commonly associated 
to CVC colonization and CRBSI, at the surface of cerium nitrate, low molecular weight 
chitosan (LMWC, 107 kDa) and hamamelitannin treated catheters; and (3) the 
evaluation of the in vivo efficacy of such coated catheters in the prevention of biofilm 
formation. 
Regarding the first objective, a retrospective study of a laboratorial database was 
performed. Positive results from the culture of CVCs removed from ICU patients and 
the antimicrobial susceptibility pattern of isolates were reviewed. As expected, the 
aetiology of CVC colonization was similar to international data: S. epidermidis was the 
most frequent isolate, followed by S. aureus, Enterobacteriaceae, Candida spp, 
Pseudomonas aeruginosa, enterococci and A. baumannii. However, higher 
antimicrobial resistance rates of S. aureus to methicillin, of E. faecium to vancomycin 
and of P. aeruginosa and A. baumannii to carbapenems were found. Conversely, 
Enterobacteriaceae displayed high susceptibility to cephalosporins, while no resistance 
to azole antifungals was detected among Candida isolates. Routine surveillance for 
antimicrobial resistance and the prospective evaluation of new therapeutic protocols 
based on the local patterns of susceptibility might help to pursue a more strict selection 
of antimicrobials in this hospital. 
Concerning the second objective, the antibiofilm effect of cerium nitrate, 
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LMWC and hamamelitannin was tested with S. epidermidis, S. aureus, A. baumannii 
and C. albicans strains. In vitro biofilm formation was assessed on polyurethane 
catheter segments and the metabolic activity was quantified by colorimetry. Cerium 
nitrate and LMWC displayed an effective microbicidal effect upon all the tested strains. 
Moreover, at subinhibitory concentrations, catheters treated with cerium nitrate were 
effective against C. albicans biofilm formation; catheters treated with LMWC inhibited 
S. epidermidis and C. albicans biofilm formation; and catheters treated with 
hamamelitannin inhibited the biofilm formation by all the tested bacteria. The in vitro 
activity against A. baumannii biofilm was an original description. 
Since the results obtained were so promising, the pursuit of the third objective 
was addressed using all the compounds. The in vivo antibiofilm effect of cerium nitrate, 
LMWC and hamamelitannin was tested at subinhibitory concentrations, using a mouse 
foreign body infection model with catheter segments. Biofilm formation was assessed 
both with a crystal violet assay, a tetrazolium reduction assay and with scanning 
electron microscopy imaging. Results were found to be similar to those previously 
documented in vitro.  
In summary, it was demonstrated that cerium nitrate, LMWC and 
hamamelitannin could be effective alternatives for the development of a more cost-
effective and biocompatible indwelling catheter, reducing CRBSIs more effectively than 
the present available options. 
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Os doentes admitidos em Unidades de Cuidados Intensivos (UCI) são frequentemente 
submetidos a cateterização venosa central (CVC). Consequentemente, podem ocorrer 
complicações infecciosas, que variam de simples colonização do cateter a sépsis. 
Globalmente, a incidência de sépsis relacionada com cateter é elevada e o seu impacto 
sócio-económico é considerável. Staphylococcus epidermidis, Staphylococcus aureus, 
Acinetobacter baumannii e Candida albicans são muitas vezes isolados nessas 
situações. Qualquer que seja a via de contaminação, estes agentes infecciosos tendem a 
formar um biofilme nos cateteres venosos centrais, o qual promove a resistência aos 
antimicrobianos. Várias estratégias foram propostas para controlar a formação de 
biofilme, apesar da redução da taxa de infecção ter sido conseguida com sucesso e 
toxicidade variáveis. Relativamente a outras alternativas, o nitrato de cério, os 
quitosanos e o hamamelitanino são compostos biocompatíveis, pouco dispendiosos, 
com actividade antimicrobiana conhecida (embora mal esclarecida) que poderiam ser 
úteis na redução da sépsis relacionada com CVC. 
Os três objectivos principais deste estudo envolveram: (1) a determinação da 
etiologia da colonização de CVCs em doentes de UCIs de um hospital universitário 
nacional; (2) a investigação in vitro da adesão de microorganismos formadores de 
biofilme a cateteres tratados com nitrato de cério, quitosano de baixo peso molecular 
(QBPM, 107 kDa) e hamamelitanino; e (3) a avaliação in vivo da eficácia desses 
cateteres na prevenção da formação de biofilme. 
Relativamente ao primeiro objectivo, procedeu-se a um estudo retrospectivo a 
partir de uma base de dados laboratorial. Os resultados positivos do exame cultural dos 
CVCs removidos dos doentes internados em UCIs e o padrão de susceptibilidade 
antimicrobiana das estirpes isoladas foram revistos. Conforme esperado, a etiologia da 
colonização dos CVCs foi semelhante à descrita internacionalmente: S. epidermidis foi 
o isolado mais frequente, seguindo-se S. aureus, Enterobacteriaceae, Candida spp, 
Pseudomonas aeruginosa, enterococos e A. baumannii. Todavia, encontraram-se taxas 
de resistência mais elevadas do S. aureus à meticilina, do E. faecium à vancomicina e da 
P. aeruginosa e A. baumannii a carbapenemas. Pelo contrário, observou-se uma elevada 
susceptibilidade de Enterobacteriaceae a cefalosporinas e nenhuma resistência de 
Candida a azoles. A vigilância rotineira da resistência antimicrobiana e a avaliação 
prospectiva de novos protocolos terapêuticos baseados nos padrões locais de 
susceptibilidade poderiam ser úteis para uma utilização mais rigorosa dos 
antimicrobianos neste hospital. 
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No que diz respeito ao segundo objectivo, o efeito antibiofilme do nitrato de 
cério, QBPM e hamamelitanino foi avaliado em estirpes de S. epidermidis, S. aureus, A. 
baumannii e C. albicans. A formação de biofilme foi avaliada em segmentos de 
cateteres de poliuretano e a actividade metabólica foi quantificada por colorimetria. O 
nitrato de cério e o QBPM demonstraram um efeito microbicida sobre todas as estirpes 
testadas. Adicionalmente, em concentrações subinibitórias, os cateteres tratados com 
nitrato de cério demonstraram eficácia sobre a formação de biofilme por C. albicans; os 
cateteres tratados com QBPM inibiram o biofilme de S. epidermidis e C. albicans; e os 
cateteres tratados com hamamelitanino inibiram a formação de biofilme por todas as 
bactérias testadas, tendo, pela primeira vez, sido demonstrada a eficácia do 
hamamelitanino contra a formação de biofilme por A. baumannii. 
Finalmente, atendendo aos resultados promissores obtidos até então, foram 
utilizados segmentos de cateteres tratados com os mesmos compostos in vivo. O efeito 
antibiofilme do nitrato de cério, QBPM e hamamelitanino foi avaliado em 
concentrações subinibitórias num modelo animal de infecção de corpo estranho. A 
formação de biofilme foi avaliada por dois ensaios distintos de colorimetria e por 
microscopia electrónica de varrimento. Os resultados foram sobreponíveis aos 
observados in vitro.  
Em resumo, ficou demonstrado que o nitrato de cério, o QBPM e o 
hamamelitanino podem representar excelentes alternativas para o desenvolvimento de 
CVCs biocompatíveis e com maior eficácia na redução da taxa de infecção relacionada 
com a sua utilização, comparativamente às opções disponíveis no mercado. 
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